Hepatology

Article	Citations
	1385
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	1218
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	1123
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	686
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	477
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	411
A Possible Association Between a Nucleotide‐Binding Domain LRR‐Containing Protein Family PYD‐Containing Protein 1 Mutation and an Autoinflammatory Disease Involving Liver Cirrhosis	325
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	306
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	274
REPLY:	250
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	208
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	193
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	184
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	179
Retracted	179
Access to technology to support telehealth in areas without specialty care for liver disease	167
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	163
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	158
Reply	155
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	151
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	150
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	149
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	147
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	146
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	142

Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	138
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	131
Cover Image	129
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	127
Late-Breaking Abstracts	126
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	123
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	122
Efficacy and safety of infliximab in patients with autoimmune hepatitis	120
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	117
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	116
Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	114
Regulatory role and translational potential of CCL11 in liver fibrosis	112
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	111
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	111
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	111
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	111
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	109
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients	106
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	102
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	101
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	100
Moving beyond the liver – proteomics as a molecular footprint of systemic damage in metabolic dysfunction-associated steatotic liver disease	100
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	99
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	97
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	96
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	96
	95
	94
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	94
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	94
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	91
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	91
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	88
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	88
Instructions to Authors	88
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	88
Letter to the editor	87
Healthy peribiliary glands are necessary for successful liver transplantation	86
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	86
Erratum	85
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	85
Endpoints and New Options for Treatment of Chronic Hepatitis D	84
Epigenome‐Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer	83
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	81
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	81
Responsible Inclusion of Pregnant Individuals in Eradicating HCV	81
Immunobiology of primary sclerosing cholangitis	80
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	77
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	77
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	74

Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	74
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	74
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	74
Two Faces of Neutrophils in Liver Disease Development and Progression	74
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	73
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	73
MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes	73
Therapeutic manipulation of the microbiome in liver disease	73
Letter to the Editor: Overlooking the important factor: Hypoxia	72
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	72
REPLY:	72
Reply	71
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	71
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	70
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	70
Letter to the Editor	70
The digital determinants of liver disease	70
With Alcohol as the Fuel, COVID Is the Match	70
REPLY:	69
Much more needed in natural history of Alagille syndrome	69
Hepatology Highlights	68
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	67
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	66
Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?	66
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	65
Introducing Raymond T. Chung, M.D., Our 2021 AASLD President	65
In vivo imaging of calcium dynamics in zebrafish hepatocytes	65
Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells	64
To Be or Not to Be	64
The international quest for the imaging diagnosis of liver cancer	64
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	64
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	63
Fontan‐associated liver disease	63
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	63
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	63
A strategy of vascular‐targeted therapy for liver fibrosis	63
NAFLD‐related hepatocellular carcinoma: The growing challenge	62
Metabolic dysfunction-associated steatotic liver disease and the heart	62
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	62
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	62
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	62
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	61
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	61
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	61
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia	61
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	60
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	60
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	60
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease	59
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	59
The clot and the complicated consult	59
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	59
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	59
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	59
Reply	59
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	58
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	58
Gene Deconvolution Reveals Aberrant Liver Regeneration and Immune Cell Infiltration in Alcohol‐Associated Hepatitis	58
Enoxacin Up‐Regulates MicroRNA Biogenesis and Down‐Regulates Cytotoxic CD8 T‐Cell Function in Autoimmune Cholangitis	58
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	57
Reply	57
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	57
Hepatology Highlights	57
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	57
REPLY:	56
Future directions in acute liver failure	56
REPLY:	56
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	56
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	56
Reply	56
Pathway to global elimination of hepatitis B: HBV cure is just the first step	56
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	55
In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood	55
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma	55
Efficiently Restored Thrombopoietin Production by Ashwell‐Morell Receptor and IL‐6R Induced Janus Kinase 2/Signal Transducer and Activator of Transcription Signaling Early After Partial Hepatectomy	55
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	54
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	54
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality	54
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	53
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study	53

Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	53
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	53
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via non-canonical phosphorylation	52
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	52
Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion	52
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	52
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	52
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	52
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	52
A Transcriptomic Signature for Risk‐Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma	51
Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2–Platelet‐Derived Growth Factor Receptor Beta–Yes‐Associated Protein Signa	51
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	50
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	50
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	49
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	49
Manuscript best practices: Takeaways from a community conversation	49
REPLY:	49
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	48
Reply	48
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	48
An Unexpected Line of Defense: Hepatoprotective Eosinophils in Ischemia‐Reperfusion Injury	48
Reply	48
Oral Abstracts	48
Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet	47
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	47
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	47
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	47
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	46
Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations	46
Table of contents	46
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	46
Masthead	46
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	46
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	46
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	46
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	46
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	45
Cover Image	45
Letter to the Editor: Living Donor Liver Transplantation or Deceased Donor Liver Transplantation in High Model for End‐Stage Liver Disease Score—Which Is Better?	45
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	45
Letter to the editor: HuR in liver homeostasis	45
Imaging for better responses to immunotherapy in hepatocellular carcinoma	45
Table of contents	44
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	44
Dissecting Early Relapse in Liver Cancer, One Cell at a Time	44
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	44
Letter to the Editor: Liver Stiffness by Transient Elastography to Detect Porto‐sinusoidal Vascular Liver Disease	44
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	43
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	43
Telehealth interventions in patients with chronic liver diseases: A systematic review	42
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	42
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	42
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	42
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study	42
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	42
Promoterless, Nuclease‐Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia	42
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	42
Reply	41
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	41
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	41
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	41
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	41
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	41
Masthead	41
Presenting the new incoming editorial team for hepatology: Team members and perspectives	41
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	40
Reply	40
Cover Image	39
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	39
Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation	39
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	39
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	39
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	39
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care	39
Predicting liver outcomes with biomarker monitoring in MASLD	39
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	39
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	39
Masthead	39
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	39
Fructose‐1,6‐Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis	38
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	38
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	38
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	38
The evolving role of liver sinusoidal endothelial cells in liver health and disease	38
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	38
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	38
Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells	38
Histone Deacetylase Sirtuin 1 Promotes Loss of Primary Cilia in Cholangiocarcinoma	38
The Use of Rifaximin in Patients With Cirrhosis	37
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	37
Myofibroblast‐Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model	37
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	37
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	37
Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes	37
Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis	36